Scalper1 News
Danish drug giant Novo Nordisk missed Q1 sales estimates and lowered its full-year revenue forecast Thursday, as the loss of support from U.S. payers hurt. The stock fell 2.9%. Novo Nordisk (NVO) made 45 cents a share in the quarter, up about 10% over the year-earlier quarter in Danish kroner, and a penny above analysts’ consensus. Sales increased 7% in local currencies to the equivalent of $3.73 billion, missing consensus of $3.97 billion. The Scalper1 News
Scalper1 News